Treatment of non-Hodgkin's lymphoma xenografts with the HB22.7 anti-CD22 monoclonal antibody and phosphatase inhibitors improves efficacy.

Purpose: To examine the role of phosphatase inhibition on anti-CD22, HB22.7-mediated lymphomacidal effects.

Experimental Design: CD22 is a cell-surface molecule expressed on most B cell lymphomas (NHL).

Phosphatase inhibition augments anti-CD22-mediated signaling and cytotoxicity in non-hodgkin's lymphoma cells.

CD22 is a cell-surface molecule found on most B-cell lymphomas (NHL). HB22.7 is an anti-CD22 antibody that blocks CD22 ligand binding, initiates signaling, and kills NHL cells.